Skip to main content

Dapsone Disease Interactions

There are 2 disease interactions with dapsone.


Dapsone (applies to dapsone) bone marrow suppression

Major Potential Hazard, High plausibility. Applicable conditions: G-6-PD Deficiency, Bone Marrow Depression/Low Blood Counts

The use of dapsone has been associated with development of agranulocytosis, aplastic anemia, and other blood dyscrasias. Blood dyscrasias are more likely to occur in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. Patients should be instructed to report any signs of infection (sore throat, fever, local infection, bleeding, or symptoms of anemia). Monitoring for hematologic abnormalities is recommended.


  1. Laing A (1980) "Unusual reaction to intramuscular sulfone in two leprosy patients in malaysia." Int J Lepr, 48, p. 70
  2. McConkey B (1981) "Adverse reactions to dapsone." Lancet, 2, p. 525
  3. Cook I, Kish M (1985) "Haematological safety of long-term malarial prophylaxis with dapsone-pyrimethamine." Med J Aust, 143, p. 139-41
  4. Potter M, Yates P, Slade R, Kennedy C (1989) "Agranulocytosis caused by dapsone therapy for granuloma annulare." J Am Acad Dermatol, 20, p. 87-8
  5. Hornsten P, Keisu M, Wiholm B (1990) "The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988." Arch Dermatol, 126, p. 919-22
  6. Duhra P, Charles-Holmes R (1991) "Linear IgA disease with haemorrhagic pompholyx and dapsone-induced neutropenia." Br J Dermatol, 125, p. 172-4
  7. Kraus A, Jakez J, Palacios A (1992) "Dapsone induced sulfone syndrome and systemic lupus exacerbation." J Rheumatol, 19, p. 178-9
  8. (2022) "Product Information. Dapsone (dapsone)." Jacobus Pharmaceutical Company
  9. Cockburn EM, Wood SM, Waller PC, Bleehen SS (1993) "Dapsone-induced agranulocytosis: spontaneous reporting data." Br J Dermatol, 128, p. 702-3
  10. Woodbury GR, Jr Fried W, Ertle JO, Malkinson FD (1993) "Dapsone-associated agranulocytosis and severe anemia in a patient with leukocytoclastic vasculitis." J Am Acad Dermatol, 28, p. 781-3
  11. Meyerson MA, Cohen PR (1994) "Dapsone-induced aplastic anemia in a woman with bullous systemic lupus erythematosus." Mayo Clin Proc, 69, p. 1159-62
  12. Raizman MB, Fay AM, Weiss JS (1994) "Dapsone induced neutropenia in patients treated for ocular cicatricial pemphigoid." Ophthalmology, 101, p. 1805-7
View all 12 references

Dapsone (applies to dapsone) liver disease

Moderate Potential Hazard, Moderate plausibility.

The use of dapsone has been associated with the development of hyperbilirubinemia. Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency are more likely to develop hyperbilirubinemia. Monitoring liver function is recommended and discontinuation of the drug may be necessary.


  1. May DG, Arns PA, Richards WO, et al. (1992) "The disposition of dapsone in cirrhosis." Clin Pharmacol Ther, 51, p. 689-700
  2. Fleming CM, Branch RA, Wilkinson GR, Guengerich FP (1992) "Human liver microsomal N-hydroxylation of dapsone by cytochrome P-4503A4." Mol Pharmacol, 41, p. 975-80
  3. Mills J, Leoung G, Ileana M, Hopewell PC, Hughes WT, Wofsy C (1988) "Dapsone treatment of pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome." Antimicrob Agents Chemother, 32, p. 1057-60
  4. (2022) "Product Information. Dapsone (dapsone)." Jacobus Pharmaceutical Company
  5. Beumont MG, Graziani A, Ubel PA, Macgregor RR (1996) "Safety of dapsone as pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole." Am J Med, 100, p. 611-6
View all 5 references

Dapsone drug interactions

There are 230 drug interactions with dapsone.

Report options

QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.